Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00929331
First received: June 25, 2009
Last updated: January 5, 2012
Last verified: February 2011
  Purpose

This study is designed to test the safety and immunogenicity of Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.


Condition Intervention Phase
Influenza
Influenza, Human
Biological: Fluviral®
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies [ Time Frame: At Day 0 ] [ Designated as safety issue: No ]
    Data are displayed as GMTs for each of the three influenza virus vaccine strains: A/Brisbane(H1N1); A/Uruguay(H3N2); B/Brisbane.

  • GMTs of HI Antibodies [ Time Frame: At Day 21 after vaccination ] [ Designated as safety issue: No ]
    Data are displayed as GMTs for each of the three influenza virus vaccine strains: A/Brisbane(H1N1); A/Uruguay(H3N2); B/Brisbane.

  • Number of Subjects With a Serum HI Titer Equal to or Above the Cut-off Value [ Time Frame: At Day 0 ] [ Designated as safety issue: No ]

    The cut-off value was defined as a serum HI titer >= 1:40, which is usually accepted as indicating protection.

    Data are displayed for each of the three influenza virus vaccine strains: A/Brisbane(H1N1); A/Uruguay(H3N2); B/Brisbane.


  • Number of Subjects With a Serum HI Titer Equal to or Above the Cut-off Value [ Time Frame: At Day 21 after vaccination ] [ Designated as safety issue: No ]

    The cut-off value was defined as a serum HI titer >= 1:40, which is usually accepted as indicating protection.

    Data are displayed for each of the three influenza virus vaccine strains: A/Brisbane(H1N1); A/Uruguay(H3N2); B/Brisbane.


  • Number of Seroconverted Subjects [ Time Frame: At Day 21 after vaccination ] [ Designated as safety issue: No ]

    A seroconverted subject is a subject who had either a prevaccination titer < 1:10 and a post-vaccination titer >= 1:40 or a pre-vaccination titer >= 1:10 and at least a four-fold increase in post-vaccination titer.

    Data are displayed for each of the three influenza virus vaccine strains: A/Brisbane(H1N1); A/Uruguay(H3N2); B/Brisbane.


  • Seroconversion Factors [ Time Frame: At Day 21 after vaccination ] [ Designated as safety issue: No ]

    Seroconversion factors are defined as the fold increase in serum HI GMTs post-vaccination (Day 21) compared to pre-vaccination (Day 0).

    Data are displayed for each of the three influenza virus vaccine strains: A/Brisbane(H1N1); A/Uruguay(H3N2); B/Brisbane.


  • Number of Subjects With a Pre-vaccination Titer Below the Cut-off Value and a Post-vaccination Titer Equal to or Above the Cut-off Value [ Time Frame: At Day 21 after vaccination ] [ Designated as safety issue: No ]

    The cut-off value was a titer of 1:40.

    Data are displayed for each of the three influenza virus vaccine strains: A/Brisbane(H1N1); A/Uruguay(H3N2); B/Brisbane.



Secondary Outcome Measures:
  • Number of Subjects Reporting Any Solicited Local Symptoms [ Time Frame: During a 4-day (Day 0-3) follow-up period after vaccination ] [ Designated as safety issue: No ]

    Solicited local symptoms assessed include pain, redness and swelling at the site of injection.

    Any = Solicited local symptoms are presented regardless of their intensity grade


  • Number of Subjects Reporting Grade 3 Solicited Local Symptoms [ Time Frame: During a 4-day (Day 0-3) follow-up period after vaccination ] [ Designated as safety issue: No ]

    Solicited local symptoms assessed include pain, redness and swelling at the site of injection.

    Grade 3 pain = pain that prevented normal activity, Grade 3 redness/swelling = redness/swelling > 100 mm


  • Number of Subjects Reporting Any Solicited General Symptoms [ Time Frame: During a 4-day (Day 0-3) follow-up period after vaccination ] [ Designated as safety issue: No ]

    Solicited local symptoms assessed include bronchospasm, chills, cough, fatigue, headache, joint pain at other location, muscle aches, red eyes, sore throat, swelling of the face, temperature (orally) in degrees celsius.

    Any = solicited general symptoms are presented regardless of their intensity grade or relationship to vaccination.

    For temperature this means equal to or above 38.0 degrees celsius.


  • Number of Subjects Reporting Grade 3 Solicited General Symptoms [ Time Frame: During a 4-day (Day 0-3) follow-up period after vaccination ] [ Designated as safety issue: No ]

    Solicited local symptoms assessed include bronchospasm, chills, cough, fatigue, headache, joint pain at other location, muscle aches, red eyes, sore throat, swelling of the face, temperature (orally) in degrees celsius.

    Grade 3 general symptom = symptom that prevented normal activity Grade 3 temperature = temperature above 39.0 degrees celsius


  • Number of Subjects Reporting Related Solicited General Symptoms [ Time Frame: During a 4-day (Day 0-3) follow-up period after vaccination ] [ Designated as safety issue: No ]

    Solicited local symptoms assessed include bronchospasm, chills, cough, fatigue, headache, joint pain at other location, muscle aches, red eyes, sore throat, swelling of the face, temperature (orally) in degrees celsius.

    Related = general symptom assessed by the investigator as related to the vaccine


  • Number of Subjects Reporting Unsolicited Adverse Events (AEs) [ Time Frame: During a 21-day (Day 0-20) follow-up period after vaccination ] [ Designated as safety issue: No ]

    Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Any = unsolicited adverse event regardless of intensity. Grade 3 = unsolicited AE that prevented normal activity Related = unsolicited AE assessed by the investigator as related to the vaccination.


  • Number of Subjects With Serious Adverse Events [ Time Frame: From the beginning up to the end of the study (Day 0 - Day 21) ] [ Designated as safety issue: No ]
    SAEs assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.


Enrollment: 110
Study Start Date: July 2009
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fluviral Adult Group
Subjects aged between 18 and 60 years who received one dose of Fluviral® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
Biological: Fluviral®
Intramuscular injection, one dose
Experimental: Fluviral Elderly Group
Subjects over 60 years of age who received one dose of Fluviral ® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
Biological: Fluviral®
Intramuscular injection, one dose

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
  • Written informed consent obtained from the subject
  • Male and female adults, 18 to 60 years of age and over 60 years of age.
  • Satisfactory baseline medical assessment by history and physical examination
  • Comprehension of the study requirements, ability to comprehend and comply with procedures for collection of safety data, expressed availability for the required study period, and ability and willingness to attend scheduled visits.
  • Female subjects of non-childbearing potential may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate contraception for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion Criteria:

  • Participation in previous year's (2008) Fluviral® registration study
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s)/product(s) within 30 days preceding the first dose of study vaccine/product, or planned use during the study period.
  • Acute disease at the time of enrollment. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. oral temperature <38.0°C.
  • Significant acute or chronic, uncontrolled medical or psychiatric illness. "Uncontrolled" is defined as:

Requiring institution of new medical or surgical treatment within one (1) month prior to study enrollment, or Requiring the re-institution of a previously discontinued medication or medical treatment within one month prior to study enrollment, or Requiring a change in medication dosage in the one month prior to study enrollment due to uncontrolled symptoms or drug toxicity (elective dosage adjustments in stable subjects are acceptable), or Hospitalization or an event fulfilling the definition of a SAE within one month prior to study enrollment.

• Any confirmed or suspected immunosuppressive condition including: History of human immunodeficiency virus (HIV) infection, Cancer or treatment for cancer, within 3 years of study enrollment. Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible.

  • History of renal impairment.
  • History of hepatic dysfunction due to hepatitis B, C or toxins including alcohol.
  • Complicated insulin-dependent diabetes mellitus.
  • Unstable cardiopulmonary disease requiring chronic medical therapy or associated with functional impairment.
  • Presence of blood dyscrasias, including hemoglobinopathies and myelo- or lymphoproliferative disorder.
  • Receipt of systemic glucocorticoids within 1 month of study enrollment, or any cytotoxic or immunosuppressive drugs within six months of study enrollment. Inhaled and topical steroids are allowed.
  • A history of any demyelinating disease including Multiple Sclerosis and Guillain-Barré syndrome.
  • Presence of an active neurological disorder.
  • History of chronic alcohol consumption and/or drug abuse.
  • Any significant disorder of coagulation that increases the risk of intramuscular injections or treatment with coumadin derivatives or heparin. Persons receiving prophylactic antiplatelet medications, e.g. low-dose aspirin, and without a clinically-apparent bleeding tendency are eligible.
  • Receipt of an influenza vaccine within 6 months prior to study enrollment.
  • Administration of any vaccines within 30 days prior to study enrollment or during the study period. Subjects who receive such treatment after enrollment will be followed per protocol and included in the safety analysis, but excluded from the according-to-protocol cohort.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or planned during the study.
  • Any known or suspected allergy to any constituent of Fluviral® and/or a history of anaphylactic type reaction to constituent of the vaccine.
  • A history of severe adverse reaction to a previous influenza vaccination.
  • Lactating/nursing female.
  • Any condition which, in the opinion of the investigator, prevents the subject from participation in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00929331

Locations
Canada, Quebec
GSK Investigational Site
Sherbrooke, Quebec, Canada, J1H 1Z1
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT00929331     History of Changes
Other Study ID Numbers: 110586
Study First Received: June 25, 2009
Results First Received: July 15, 2010
Last Updated: January 5, 2012
Health Authority: Canada: Health Canada

Keywords provided by GlaxoSmithKline:
Influenza
Fluviral®

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases

ClinicalTrials.gov processed this record on November 20, 2014